ASCO-GU – picking apart Exelixis’s Contact-02 win
A rare success for Cabometyx sees a survival benefit, but the control regimen raises questions.
A rare success for Cabometyx sees a survival benefit, but the control regimen raises questions.
The Merck & Co drug's first successful phase 3 study might not be all it’s cracked up to be.
A flurry of activity around USP1 inhibition suggests growing interest in this novel DNA damage response mechanism.
However, the design of the Contact-02 study, and the relevance of the positive PFS endpoint, will be debated.